<p>Insulet Corporation（纳斯达克代码：PODD - 获取免费报告）在周三的交易中创下了 52 周的新低，此前 BTIG Research 将该股票的目标价从 320.00 美元下调至 260.00 美元。BTIG Research 目前对该股票维持买入评级。Insulet 的股价最低曾达到 152.25 美元，最后交易价为 159.5110 美元，成交量为 409686 股。该股票此前收盘价为 167.53 美元。</p>
<ul>
<li>2025 年表现优异的 3 只医疗科技股票</li>
</ul>
<p>其他研究分析师最近也对该公司发布了研究报告。高盛集团在 4 月 8 日的研究报告中将 Insulet 的目标价从 326.00 美元下调至 277.00 美元，并对该股票给予 “买入” 评级。Leerink Partners 在 2 月 19 日的研究报告中将 Insulet 的目标价从 386.00 美元下调至 360.00 美元，并给予 “跑赢大盘” 评级。TD Cowen 在 1 月 26 日的研究报告中将 Insulet 的评级从 “买入” 下调至 “持有”，并设定了 294.00 美元的目标价。Raymond James Financial 在 2 月 19 日的研究报告中将 Insulet 的目标价从 385.00 美元下调至 355.00 美元，并给予 “跑赢大盘” 评级。最后，Canaccord Genuity Group 在 2 月 18 日的研究报告中将 Insulet 的目标价从 450.00 美元下调至 435.00 美元，并给予 “买入” 评级。共有 18 位研究分析师对该股票给予买入评级，5 位给予持有评级，1 位给予卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 324.38 美元。</p>
<p><strong>阅读我们对 PODD 的最新分析</strong></p>
<h2>内部活动</h2>
<ul>
<li>Insulet 在第一季度业绩超预期，成为标准普尔 500 指数的顶级表现者</li>
</ul>
<p>在相关消息中，董事 Michael R. Minogue 在 2 月 25 日的交易中购买了 2030 股该公司的股票。每股购买价格为 246.23 美元，总交易额为 499,846.90 美元。购买后，该董事在公司持有 17,483 股，价值 4,304,839.09 美元。此次交易使其持股增加了 13.14%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。公司内部人士持有公司股票的 0.36%。</p>
<h2>Insulet 的关键新闻</h2>
<p>以下是本周影响 Insulet 的关键新闻：</p>
<ul>
<li>积极情绪：第一季度业绩大幅超出预期——每股收益 1.42 美元（与约 1.19 美元的共识相比）和收入 761.7 百万美元（同比增长 33.9%）。这确认了强劲的 Omnipod 需求。Insulet 发布 2026 年第一季度业绩</li>
<li>积极情绪：公司提高了年度收入增长/前景，得益于持续的 Omnipod 采用——这是中长期收入增长的积极信号。Insulet 在季度业绩超预期后上调年度收入预测</li>
<li>积极情绪：研发/临床进展：Insulet 启动了 EVOLVE 关键研究，以推进完全闭环的自动胰岛素输送系统——对长期产品管道价值有积极影响。Insulet 启动 EVOLVE 关键研究</li>
<li>中性情绪：BTIG 将其目标价从 320 美元下调至 260 美元，但维持买入评级——这仍然暗示从当前水平有显著的上涨空间，尽管下调信号表明近期预期更加保守。Benzinga</li>
<li>中性情绪：一些分析师/技术分析指出，该股票在近期被超卖，如果卖压减轻，可能会出现均值回归。Zacks：趋势反转可能即将到来</li>
<li>消极情绪：全年每股收益指引（约 6.21）略低于共识（约 6.33），这可能在超预期后限制了反弹，并促使一些获利了结。Insulet：第一季度收益快照</li>
<li>消极情绪：较大的日内成交量和相对于 50 日和 200 日移动平均线的急剧短期下跌表明技术性卖压加剧了下跌。MSN：Insulet 报告第一季度业绩乐观</li>
</ul>
<h2>对 Insulet 的对冲基金看法</h2>
<ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
<p>大型投资者最近对该公司的持仓进行了调整。Larson Financial Group LLC 在第四季度将其在 Insulet 的持仓提高了 114.6%。Larson Financial Group LLC 目前持有 88 股该医疗器械供应商的股票，价值 25,000 美元，此前在上个季度又购买了 47 股。德克萨斯大学投资管理公司在第四季度获得了 Insulet 的新头寸，价值约 26,000 美元。Elyxium Wealth LLC 在第四季度获得了 Insulet 的新头寸，价值约 28,000 美元。DV Equities LLC 在第四季度获得了 Insulet 的新头寸，价值约 28,000 美元。最后，MV Capital Management Inc.在第四季度获得了 Insulet 的新头寸，价值约 29,000 美元。</p>
<h2>Insulet 股票下跌 9.8%</h2>
<p>该公司的流动比率为 2.81，速动比率为 2.15，债务与股本比率为 0.61。该公司的市值为 104.7 亿美元，市盈率为 43.18，PEG 比率为 1.01，贝塔值为 1.20。该公司的 50 日移动平均线为 214.88 美元，200 日移动平均线为 266.12 美元。</p>
<p>Insulet（纳斯达克代码：PODD - 获取免费报告）最近在 5 月 6 日发布了季度财报。这家医疗器械供应商报告第一季度每股收益为 1.42 美元，超出市场共识预期的 1.19 美元，超出幅度为 0.23 美元。Insulet 的股本回报率为 24.90%，净利润率为 9.12%。该公司在本季度的收入为 7.617 亿美元，而分析师预期为 7.2989 亿美元。与去年同期相比，该公司的收入增长了 33.9%。Insulet 已将其 2026 财年的指引设定为每股收益 6.210。整体来看，卖方分析师预测 Insulet Corporation 在当前财年将发布每股收益 6.27。</p>
<h2>关于 Insulet</h2>
<p>（获取免费报告）</p>
<p>Insulet Corporation 是一家总部位于马萨诸塞州阿克顿的医疗设备公司，专注于开发、制造和销售糖尿病患者的胰岛素输送系统。公司的核心业务是设计和商业化其 Omnipod 系列无管道、可穿戴的胰岛素泵及其输送胰岛素的消耗品 Pods。Insulet 的产品旨在为 1 型糖尿病和需要胰岛素的 2 型糖尿病患者简化胰岛素输送，提供传统胰岛素笔和有线泵系统的替代方案。</p>
<p>公司的产品组合包括 Omnipod 系统系列——一次性、耐水的 Pods，能够贴附在皮肤上并输送胰岛素——以及用于编程和监控胰岛素输送的相关控制器和移动应用程序。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过 Insulet</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资$1,000 在 Insulet 吗？</h2>
<p>在考虑 Insulet 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Insulet 并不在名单上。</p>
<p>虽然 Insulet 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PODD

医药突破 ETF - ALPS

标普生物技术 3 倍做多 - Direxion

<p>Insulet Corporation（纳斯达克代码：PODD）在 BTIG Research 将其目标价从 320 美元下调至 260 美元并维持买入评级后，达到了 152.25 美元的新 52 周低点。其他分析师也下调了他们的目标价，平均目标价为 324.38 美元。尽管第一季度业绩积极且 Omnipod 需求强劲，但该股面临卖压，导致下跌 9.8%。十八位分析师给予买入评级，五位持有评级，一位卖出评级。Insulet 的财务比率显示其财务状况稳健，市值为 43 亿美元</p>

<p>Insulet Corporation (NASDAQ:PODD - Get Free Report) hit a new 52-week low during trading on Wednesday after BTIG Research lowered their price target on the stock from $320.00 to $260.00. BTIG Research currently has a buy rating on the stock. Insulet traded as low as $152.25 and last traded at $159.5110, with a volume of 409686 shares trading hands. The stock had previously closed at $167.53.</p>
<div class="lb-trans"><p>Insulet Corporation（纳斯达克代码：PODD - 获取免费报告）在周三的交易中创下了 52 周的新低，此前 BTIG Research 将该股票的目标价从 320.00 美元下调至 260.00 美元。BTIG Research 目前对该股票维持买入评级。Insulet 的股价最低曾达到 152.25 美元，最后交易价为 159.5110 美元，成交量为 409686 股。该股票此前收盘价为 167.53 美元。</p>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年表现优异的 3 只医疗科技股票</li>
</ul>
</div><p>Other research analysts also recently issued research reports about the company. The Goldman Sachs Group lowered their target price on Insulet from $326.00 to $277.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, April 8th. Leerink Partners lowered their target price on Insulet from $386.00 to $360.00 and set an &#34;outperform&#34; rating on the stock in a research note on Thursday, February 19th. TD Cowen downgraded Insulet from a &#34;buy&#34; rating to a &#34;hold&#34; rating and set a $294.00 target price on the stock. in a research note on Monday, January 26th. Raymond James Financial lowered their target price on Insulet from $385.00 to $355.00 and set an &#34;outperform&#34; rating on the stock in a research note on Thursday, February 19th. Finally, Canaccord Genuity Group lowered their target price on Insulet from $450.00 to $435.00 and set a &#34;buy&#34; rating on the stock in a research note on Wednesday, February 18th. Eighteen research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average price target of $324.38.</p>
<div class="lb-trans"><p>其他研究分析师最近也对该公司发布了研究报告。高盛集团在 4 月 8 日的研究报告中将 Insulet 的目标价从 326.00 美元下调至 277.00 美元，并对该股票给予 “买入” 评级。Leerink Partners 在 2 月 19 日的研究报告中将 Insulet 的目标价从 386.00 美元下调至 360.00 美元，并给予 “跑赢大盘” 评级。TD Cowen 在 1 月 26 日的研究报告中将 Insulet 的评级从 “买入” 下调至 “持有”，并设定了 294.00 美元的目标价。Raymond James Financial 在 2 月 19 日的研究报告中将 Insulet 的目标价从 385.00 美元下调至 355.00 美元，并给予 “跑赢大盘” 评级。最后，Canaccord Genuity Group 在 2 月 18 日的研究报告中将 Insulet 的目标价从 450.00 美元下调至 435.00 美元，并给予 “买入” 评级。共有 18 位研究分析师对该股票给予买入评级，5 位给予持有评级，1 位给予卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 324.38 美元。</p>
</div><p><strong>Read Our Latest Analysis on PODD</strong></p>
<div class="lb-trans"><p><strong>阅读我们对 PODD 的最新分析</strong></p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><ul>
<li>Insulet Surges on Q1 Beat, Emerges as a Top S&amp;P 500 Performer</li>
</ul>
<div class="lb-trans"><ul>
<li>Insulet 在第一季度业绩超预期，成为标准普尔 500 指数的顶级表现者</li>
</ul>
</div><p>In related news, Director Michael R. Minogue purchased 2,030 shares of the firm's stock in a transaction dated Wednesday, February 25th. The stock was bought at an average price of $246.23 per share, for a total transaction of $499,846.90. Following the purchase, the director owned 17,483 shares in the company, valued at $4,304,839.09. The trade was a 13.14% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.36% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，董事 Michael R. Minogue 在 2 月 25 日的交易中购买了 2030 股该公司的股票。每股购买价格为 246.23 美元，总交易额为 499,846.90 美元。购买后，该董事在公司持有 17,483 股，价值 4,304,839.09 美元。此次交易使其持股增加了 13.14%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。公司内部人士持有公司股票的 0.36%。</p>
</div><h2>Key Insulet News</h2>
<div class="lb-trans"><h2>Insulet 的关键新闻</h2>
</div><p>Here are the key news stories impacting Insulet this week:</p>
<div class="lb-trans"><p>以下是本周影响 Insulet 的关键新闻：</p>
</div><ul>
<li>Positive Sentiment: Q1 results materially beat expectations — EPS $1.42 (vs. ~ $1.19 consensus) and revenue $761.7M (+33.9% y/y). This confirms strong Omnipod demand. Insulet Reports First Quarter 2026 Results</li>
<li>Positive Sentiment: Company raised its annual revenue growth/outlook driven by continued Omnipod adoption — a constructive signal for mid‑to‑long term top‑line growth. Insulet lifts annual revenue forecast after quarterly beat</li>
<li>Positive Sentiment: R&amp;D/clinical progress: Insulet initiated the EVOLVE pivotal study to advance a fully closed‑loop automated insulin delivery system — positive for long‑term product pipeline value. Insulet Initiates EVOLVE Pivotal Study</li>
<li>Neutral Sentiment: BTIG lowered its price target from $320 to $260 but kept a Buy rating — still implying significant upside from current levels, though the cut signals more conservative near‑term expectations. Benzinga</li>
<li>Neutral Sentiment: Some analysts/technicals note the stock has been oversold in recent weeks, which could set up a mean‑reversion if selling pressure eases. Zacks: Trend Reversal May Be Around the Corner</li>
<li>Negative Sentiment: Full‑year EPS guidance (~6.21) was modestly below consensus (~6.33), which likely capped the rally after the beat and prompted some profit‑taking. Insulet: Q1 Earnings Snapshot</li>
<li>Negative Sentiment: Heavy intraday volume and sharp short‑term drop versus the 50‑ and 200‑day moving averages indicate technical selling pressure amplifying the decline. MSN: Insulet reports upbeat Q1</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：第一季度业绩大幅超出预期——每股收益 1.42 美元（与约 1.19 美元的共识相比）和收入 761.7 百万美元（同比增长 33.9%）。这确认了强劲的 Omnipod 需求。Insulet 发布 2026 年第一季度业绩</li>
<li>积极情绪：公司提高了年度收入增长/前景，得益于持续的 Omnipod 采用——这是中长期收入增长的积极信号。Insulet 在季度业绩超预期后上调年度收入预测</li>
<li>积极情绪：研发/临床进展：Insulet 启动了 EVOLVE 关键研究，以推进完全闭环的自动胰岛素输送系统——对长期产品管道价值有积极影响。Insulet 启动 EVOLVE 关键研究</li>
<li>中性情绪：BTIG 将其目标价从 320 美元下调至 260 美元，但维持买入评级——这仍然暗示从当前水平有显著的上涨空间，尽管下调信号表明近期预期更加保守。Benzinga</li>
<li>中性情绪：一些分析师/技术分析指出，该股票在近期被超卖，如果卖压减轻，可能会出现均值回归。Zacks：趋势反转可能即将到来</li>
<li>消极情绪：全年每股收益指引（约 6.21）略低于共识（约 6.33），这可能在超预期后限制了反弹，并促使一些获利了结。Insulet：第一季度收益快照</li>
<li>消极情绪：较大的日内成交量和相对于 50 日和 200 日移动平均线的急剧短期下跌表明技术性卖压加剧了下跌。MSN：Insulet 报告第一季度业绩乐观</li>
</ul>
</div><h2>Hedge Funds Weigh In On Insulet</h2>
<div class="lb-trans"><h2>对 Insulet 的对冲基金看法</h2>
</div><ul>
<li>Are These 5 Undervalued Stocks Ready to Break Out?</li>
</ul>
<div class="lb-trans"><ul>
<li>这 5 只被低估的股票准备突破吗？</li>
</ul>
</div><p>Large investors have recently made changes to their positions in the business. Larson Financial Group LLC lifted its position in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. acquired a new position in shares of Insulet during the 4th quarter worth about $26,000. Elyxium Wealth LLC acquired a new position in shares of Insulet during the 4th quarter worth about $28,000. DV Equities LLC acquired a new position in shares of Insulet during the 4th quarter worth about $28,000. Finally, MV Capital Management Inc. acquired a new position in shares of Insulet during the 4th quarter worth about $29,000.</p>
<div class="lb-trans"><p>大型投资者最近对该公司的持仓进行了调整。Larson Financial Group LLC 在第四季度将其在 Insulet 的持仓提高了 114.6%。Larson Financial Group LLC 目前持有 88 股该医疗器械供应商的股票，价值 25,000 美元，此前在上个季度又购买了 47 股。德克萨斯大学投资管理公司在第四季度获得了 Insulet 的新头寸，价值约 26,000 美元。Elyxium Wealth LLC 在第四季度获得了 Insulet 的新头寸，价值约 28,000 美元。DV Equities LLC 在第四季度获得了 Insulet 的新头寸，价值约 28,000 美元。最后，MV Capital Management Inc.在第四季度获得了 Insulet 的新头寸，价值约 29,000 美元。</p>
</div><h2>Insulet Stock Down 9.8%</h2>
<div class="lb-trans"><h2>Insulet 股票下跌 9.8%</h2>
</div><p>The company has a current ratio of 2.81, a quick ratio of 2.15 and a debt-to-equity ratio of 0.61. The firm has a market cap of $10.47 billion, a price-to-earnings ratio of 43.18, a PEG ratio of 1.01 and a beta of 1.20. The firm has a 50-day moving average of $214.88 and a two-hundred day moving average of $266.12.</p>
<div class="lb-trans"><p>该公司的流动比率为 2.81，速动比率为 2.15，债务与股本比率为 0.61。该公司的市值为 104.7 亿美元，市盈率为 43.18，PEG 比率为 1.01，贝塔值为 1.20。该公司的 50 日移动平均线为 214.88 美元，200 日移动平均线为 266.12 美元。</p>
</div><p>Insulet (NASDAQ:PODD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $761.70 million during the quarter, compared to analysts' expectations of $729.89 million. During the same quarter in the previous year, the firm earned $1.02 EPS. The firm's revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts predict that Insulet Corporation will post 6.27 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Insulet（纳斯达克代码：PODD - 获取免费报告）最近在 5 月 6 日发布了季度财报。这家医疗器械供应商报告第一季度每股收益为 1.42 美元，超出市场共识预期的 1.19 美元，超出幅度为 0.23 美元。Insulet 的股本回报率为 24.90%，净利润率为 9.12%。该公司在本季度的收入为 7.617 亿美元，而分析师预期为 7.2989 亿美元。与去年同期相比，该公司的收入增长了 33.9%。Insulet 已将其 2026 财年的指引设定为每股收益 6.210。整体来看，卖方分析师预测 Insulet Corporation 在当前财年将发布每股收益 6.27。</p>
</div><h2>About Insulet</h2>
<div class="lb-trans"><h2>关于 Insulet</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.</p>
<div class="lb-trans"><p>Insulet Corporation 是一家总部位于马萨诸塞州阿克顿的医疗设备公司，专注于开发、制造和销售糖尿病患者的胰岛素输送系统。公司的核心业务是设计和商业化其 Omnipod 系列无管道、可穿戴的胰岛素泵及其输送胰岛素的消耗品 Pods。Insulet 的产品旨在为 1 型糖尿病和需要胰岛素的 2 型糖尿病患者简化胰岛素输送，提供传统胰岛素笔和有线泵系统的替代方案。</p>
</div><p>The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.</p>
<div class="lb-trans"><p>公司的产品组合包括 Omnipod 系统系列——一次性、耐水的 Pods，能够贴附在皮肤上并输送胰岛素——以及用于编程和监控胰岛素输送的相关控制器和移动应用程序。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Insulet</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过 Insulet</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Insulet Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Insulet 吗？</h2>
</div><p>Before you consider Insulet, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Insulet 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Insulet 并不在名单上。</p>
</div><p>While Insulet currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insulet 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Insulet (NASDAQ:PODD) Hits New 52-Week Low Following Analyst Downgrade

Market Beat

Insulet

标普健康医疗设备 ETF - SPDR

生物科技 ETF - VanEck Vectors

美国医药设备 ETF - iShares

纽交所高增长板生物技术指数 ETF - First Trust

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

高盛

瑞杰金融

标普 500 指数

GS Hldg R

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Insulet（纳斯达克股票代码：PODD）在分析师下调评级后跌至 52 周新低